The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.
Recent approvals and clinical trial results continue to enhance the treatment landscape for patients with non–muscle-invasive and muscle-invasive bladder cancer.
Systemic therapies are critical to the treatment of muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic bladder cancer. Recent approvals and clinical trial results continue to enhance the treatment landscape in this space.
Systemic therapies are critical to the treatment of muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic bladder cancer. Recent approvals and clinical trial results continue to enhance the treatment landscape in this space.
Recent approvals and clinical trial results continue to enhance treatment options for both BCG-resistant non-muscle invasive bladder cancer and locally advanced/metastatic bladder cancer. Clinicians should be knowledgeable in these recent updates as well as understand how to apply them to their clinical practice.
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.
Systemic therapy options for advanced bladder cancer continue to expand. The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research
Facebook
X
LinkedIn
Forward